On the other hand, intratumoral injection of liposomal anti-EphA2 reduces 43.1% of tumor volume in gastric cancer cell which is need to be further analyzed in systemic administration to make it feasible for use in human. The gene discussed is EPHA2; the disease is neoplasm.